Effect of GH on the Blastocyst Euploid Rate in AMA Patients

Launched by SHANGHAI JI AI GENETICS & IVF INSTITUTE · Jul 3, 2022

Keywords

ClinConnect Summary

This clinical trial is studying whether adding growth hormone (GH) supplements can improve the quality of embryos in women over the age of 38 who are having trouble getting pregnant. The goal is to see if using GH before and during the ovarian stimulation process (where medications help the ovaries produce eggs) can increase the number of healthy embryos that can be tested for genetic issues. Women who meet the criteria, such as being 38 years or older and planning to undergo a specific genetic test called PGT-A (which checks embryos for chromosome problems), may be eligible to participate.

Participants will be randomly assigned to one of two groups: one group will receive the growth hormone along with their fertility treatment, while the other group will only receive the standard fertility treatment without the hormone. The main outcome being measured is the rate of healthy embryos produced, which is crucial for successful pregnancy. If you or someone you know is interested in participating, it’s important to note that certain conditions, like severe endometriosis or specific uterine abnormalities, may prevent eligibility. The trial is currently recruiting participants, and those interested will need to provide informed consent before joining.

Gender

FEMALE

Eligibility criteria

• Inclusion Criteria:
• • Age ≥38; intended to undergo PGT-A
• • BMI in the normal range (18.50-24.0kg/m2)
• • Normal semen analysis for the male partner
• Exclusion Criteria:
• • Endometriosis grade 3 or higher, untreat hydrosalpinx
• • Women with a uterine cavity abnormality, such as a uterine congenital malformation (uterus uni-cornate, bicornate, or duplex); untreated uterine septum, adenomyosis, submucous myoma, or endo-metrial polyp(s)
• • Women who are indicated and planned to undergo PGT-SR (Preimplantation genetic testing for structural rearrangement) or PGT-M (Preimplantation genetic testing for monogenic disorder), for example, parental abnormal karyo-type or diagnosed with monogenic disease
• • History of endocrine disorder, autoimmune diseases or diagnosed thrombophilia
• • History of GH supplementation in the previous IVF treatment or taking other supplementary drugs used during stimulation; patients with absolute or relative contraindications to GH treatment, including active malignancy or history of cancer, diabetic retinopathy, diabetes mellitus, and chronic kidney disease.